{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:13:20Z","timestamp":1753892000177,"version":"3.41.2"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000092","name":"U.S. National Library of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000092","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Coumadin (R\/S-warfarin) anticoagulant therapy is highly efficacious in preventing the formation of blood clots; however, significant inter-individual variations in response risks over or under dosing resulting in adverse bleeding events or ineffective therapy, respectively. Levels of pharmacologically active forms of the drug and metabolites depend on a diversity of metabolic pathways. Cytochromes P450 play a major role in oxidizing R- and S-warfarin to 6-, 7-, 8-, 10-, and 4\u2032-hydroxywarfarin, and warfarin alcohols form through a minor metabolic pathway involving reduction at the C11 position. We hypothesized that due to structural similarities with warfarin, hydroxywarfarins undergo reduction, possibly impacting their pharmacological activity and elimination. We modeled reduction reactions and carried out experimental steady-state reactions with human liver cytosol for conversion of <jats:italic>rac<\/jats:italic>-6-, 7-, 8-, 4\u2032-hydroxywarfarin and 10-hydroxywarfarin isomers to the corresponding alcohols. The modeling correctly predicted the more efficient reduction of 10-hydroxywarfarin over warfarin but not the order of the remaining hydroxywarfarins. Experimental studies did not indicate any clear trends in the reduction for <jats:italic>rac<\/jats:italic>-hydroxywarfarins or 10-hydroxywarfarin into alcohol 1 and 2. The collective findings indicated the location of the hydroxyl group significantly impacted reduction selectivity among the hydroxywarfarins, as well as the specificity for the resulting metabolites. Based on studies with R- and S-7-hydroxywarfarin, we predicted that all hydroxywarfarin reductions are enantioselective toward <jats:italic>R<\/jats:italic> substrates and enantiospecific for <jats:italic>S<\/jats:italic> alcohol metabolites. CBR1 and to a lesser extent AKR1C3 reductases are responsible for those reactions. Due to the inefficiency of reactions, only reduction of 10-hydroxywarfarin is likely to be important in clearance of the metabolite. This pathway for 10-hydroxywarfarin may have clinical relevance as well given its anticoagulant activity and capacity to inhibit <jats:italic>S<\/jats:italic>-warfarin metabolism.<\/jats:p>","DOI":"10.3389\/fphar.2021.805133","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T06:16:21Z","timestamp":1642054581000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Discovery of Novel Reductive Elimination Pathway for 10-Hydroxywarfarin"],"prefix":"10.3389","volume":"12","author":[{"given":"Dakota L.","family":"Pouncey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dustyn A.","family":"Barnette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riley W.","family":"Sinnott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noah R.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard P.","family":"Hendrickson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Joshua","family":"Swamidass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grover P.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jchromb.2013.11.014","article-title":"Determination of Warfarin Alcohols by Ultra-high Performance Liquid Chromatography-Tandem Mass Spectrometry: Application to In Vitro Enzyme Kinetic Studies","volume":"944","author":"Alshogran","year":"2014","journal-title":"J. Chromatogr. B Analyt Technol. Biomed. Life Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"160s","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1124\/dmd.117.075929","article-title":"Stereospecific Metabolism of R- and S-Warfarin by Human Hepatic Cytosolic Reductases","volume":"45","author":"Barnette","year":"2017","journal-title":"Drug Metab. Dispos"},{"key":"B4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1124\/jpet.111.184721","article-title":"Analysis of R- and S-Hydroxywarfarin Glucuronidation Catalyzed by Human Liver Microsomes and Recombinant UDP-Glucuronosyltransferases","volume":"340","author":"Bratton","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1021\/acs.jcim.9b00836","article-title":"The Metabolic Rainbow: Deep Learning Phase I Metabolism in Five Colors","volume":"60","author":"Dang","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"B6","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1182\/blood-2013-05-505123","article-title":"A Cellular System for Quantitation of Vitamin K Cycle Activity: Structure-Activity Effects on Vitamin K Antagonism by Warfarin Metabolites","volume":"123","author":"Haque","year":"2014","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.jchromb.2011.03.022","article-title":"Novel Multi-Mode Ultra Performance Liquid Chromatography-Tandem Mass Spectrometry Assay for Profiling Enantiomeric Hydroxywarfarins and Warfarin in Human Plasma","volume":"879","author":"Jones","year":"2011","journal-title":"J. Chromatogr. B Analyt Technol. Biomed. Life Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2174\/187231210792928242","article-title":"Contribution of Three CYP3A Isoforms to Metabolism of R- and S-Warfarin","volume":"4","author":"Jones","year":"","journal-title":"Drug Metab. Lett."},{"key":"B9","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1021\/tx1000283","article-title":"Hydroxywarfarin Metabolites Potently Inhibit CYP2C9 Metabolism of S-Warfarin","volume":"23","author":"Jones","year":"","journal-title":"Chem. Res. Toxicol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1517\/17425255.2011.576247","article-title":"Assays and Applications in Warfarin Metabolism: what We Know, How We Know it and what We Need to Know","volume":"7","author":"Jones","year":"2011","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/03602530903209395","article-title":"Warfarin and UDP-Glucuronosyltransferases: Writing a New Chapter of Metabolism","volume":"42","author":"Jones","year":"","journal-title":"Drug Metab. Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/s0163-7258(96)00140-4","article-title":"Human P450 Metabolism of Warfarin","volume":"73","author":"Kaminsky","year":"1997","journal-title":"Pharmacol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1124\/dmd.108.022251","article-title":"Carbonyl Reductase 1 Is a Predominant Doxorubicin Reductase in the Human Liver","volume":"36","author":"Kassner","year":"2008","journal-title":"Drug Metab. Dispos"},{"key":"B14","unstructured":"Kendan AlexanderJ-I.\n          Seattle, WashingtonUniversity of WashingtonThe Impact of R10-Hydroxywarfarin on CYP2C9-Mediated S-Warfarin Metabolism2014"},{"key":"B15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/00498254.2018.1451668","article-title":"Regioselectivity Significantly Impacts Microsomal Glucuronidation Efficiency of R\/S-6, 7-, and 8-hydroxywarfarin","volume":"49","author":"Kim","year":"2019","journal-title":"Xenobiotica"},{"key":"B16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jyp.2013.02.001","article-title":"Estimation of Plasma Levels of Warfarin and 7-hydroxy Warfarin by High Performance Liquid Chromatography in Patients Receiving Warfarin Therapy","volume":"5","author":"Krishna Kumar","year":"2013","journal-title":"J. Young Pharm."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1172\/JCI107711","article-title":"Warfarin. Stereochemical Aspects of its Metabolism and the Interaction with Phenylbutazone","volume":"53","author":"Lewis","year":"1974","journal-title":"J. Clin. Invest."},{"key":"B18","doi-asserted-by":"publisher","first-page":"925","DOI":"10.5555\/URI:PII:0022214373903144","article-title":"Warfarin Metabolites: the Anticoagulant Activity and Pharmacology of Warfarin Alcohols","volume":"81","author":"Lewis","year":"1973","journal-title":"J. Lab. Clin. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jchromb.2004.12.024","article-title":"Determination of Warfarin Enantiomers and Hydroxylated Metabolites in Human Blood Plasma by Liquid Chromatography with Achiral and Chiral Separation","volume":"818","author":"Locatelli","year":"2005","journal-title":"J. Chromatogr. B Analyt Technol. Biomed. Life Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.bcp.2016.03.025","article-title":"Carbonyl Reduction of Warfarin: Identification and Characterization of Human Warfarin Reductases","volume":"109","author":"Mal\u00e1tkov\u00e1","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3109\/03602532.2013.853078","article-title":"Carbonyl Reduction Pathways in Drug Metabolism","volume":"46","author":"Mal\u00e1tkov\u00e1","year":"2014","journal-title":"Drug Metab. Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1021\/tx900031z","article-title":"Assessing Cytochrome P450 and UDP-Glucuronosyltransferase Contributions to Warfarin Metabolism in Humans","volume":"22","author":"Miller","year":"2009","journal-title":"Chem. Res. Toxicol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1111\/j.1538-7836.2010.04097.x","article-title":"Warfarin Therapy: How the Less Interesting Half Just Got Interesting","volume":"8","author":"Miller","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"B24","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1097\/MBC.0000000000000752","article-title":"Novel Isomeric Metabolite Profiles Correlate with Warfarin Metabolism Phenotype during Maintenance Dosing in a Pilot Study of 29 Patients","volume":"29","author":"Pouncey","year":"2018","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.abb.2014.10.006","article-title":"Multiple UDP-Glucuronosyltransferases in Human Liver Microsomes Glucuronidate Both R- and S-7-Hydroxywarfarin into Two Metabolites","author":"Pugh","year":"2018","journal-title":"Arch. Biochem. Biophys."},{"key":"B26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1021\/tx00025a009","article-title":"Hydroxylation of Warfarin by Human cDNA-Expressed Cytochrome P-450: a Role for P-4502C9 in the Etiology of (S)-warfarin-drug Interactions","volume":"5","author":"Rettie","year":"1992","journal-title":"Chem. Res. Toxicol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1111\/j.1538-7836.2010.04036.x","article-title":"Stereoselective Interactions of Warfarin Enantiomers with the Pregnane X Nuclear Receptor in Gene Regulation of Major Drug-Metabolizing Cytochrome P450 Enzymes","volume":"8","author":"Rulcova","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/archinte.167.13.1414","article-title":"Bleeding Complications with Warfarin Use: a Prevalent Adverse Effect Resulting in Regulatory Action","volume":"167","author":"Wysowski","year":"2007","journal-title":"Arch. Intern. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1124\/jpet.107.129858","article-title":"Glucuronidation of Monohydroxylated Warfarin Metabolites by Human Liver Microsomes and Human Recombinant UDP-Glucuronosyltransferases","volume":"324","author":"Zielinska","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.805133\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T06:16:23Z","timestamp":1642054583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.805133\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":29,"alternative-id":["10.3389\/fphar.2021.805133"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.805133","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2022,1,13]]},"article-number":"805133"}}